Skip to main content

Table 2 Baseline characteristics

From: Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study

Variables Adjuvant chemotherapy cycles Not received (A) 7–8 or 10–12 cycles (B) 4–6 or 6–9 cycles (C) ≤3 or 5 cycles (D)
P P P P
Age Not received (A)   < 0.001 < 0.001 0.019
7–8 or 10–12 cycles (B) < 0.001   0.043 < 0.001
4–6 or 6–9 cycles (C) < 0.001 0.043   0.060
≤3 or 5 cycles (D) 0.019 < 0.001 0.060  
BMI Not received (A)   0.008 0.356 0.095
7–8 or 10–12 cycles (B) 0.008   0.080 0.650
4–6 or 6–9 cycles (C) 0.356 0.080   0.361
≤3 or 5 cycles (D) 0.095 0.650 0.361  
Postoperative complications Not received (A)   < 0.001 0.009 0.054
7–8 or 10–12 cycles (B) < 0.001   0.405 0.310
4–6 or 6–9 cycles (C) 0.009 0.405   0.782
≤3 or 5 cycles (D) 0.054 0.310 0.782  
Tumor length/diameter Not received (A)   0.361 0.474 0.029
7–8 or 10–12 cycles (B) 0.361   0.893 0.001
4–6 or 6–9 cycles (C) 0.474 0.893   0.004
≤3 or 5 cycles (D) 0.029 0.001 0.004  
  1. Note: P < 0.05, statistically significant; P values for pairwise comparisons